» Articles » PMID: 9525993

Clearance of HSV-2 from Recurrent Genital Lesions Correlates with Infiltration of HSV-specific Cytotoxic T Lymphocytes

Overview
Journal J Clin Invest
Specialty General Medicine
Date 1998 Apr 29
PMID 9525993
Citations 131
Authors
Affiliations
Soon will be listed here.
Abstract

The mechanisms involved in host clearance of symptomatic mucocutaneous herpes simplex virus (HSV) infection are unclear. We studied the functional properties of bulk cultures of skin-infiltrating lymphocytes from normal skin and serial biopsies of recurrent genital HSV-2 lesions, and compared HSV-specific and NK responses with viral clearance. HSV-specific CD4+ or CD8+ T cells were rarely detected in lymphocytes cultured from normal skin. The total lymphocyte count and HSV-specific and NK-like effector cell activities were markedly higher in cultures derived from lesional skin. HSV-specific CD4+ proliferative responses and NK-like cytotoxic responses were present at all stages of herpetic lesions, including biopsies early in the disease course. In contrast, cytotoxic T lymphocyte activity was generally low among cells derived from early culture-positive lesions, and increased during lesion evolution. Viral clearance from the lesion site was associated with a high level of local cytolytic activity towards HSV-infected cells. The phenotypes of cells with HSV-specific cytotoxic responses varied between patients, having CD4+ and CD8+ components. Immunotherapeutic approaches to HSV should be directed at improving in vivo cytolytic activity to HSV.

Citing Articles

A replication-incompetent adenoviral vector encoding for HSV-2 gD2 is immunogenic and protective against HSV-2 intravaginal challenge in mice.

Rossetti E, Vujadinovic M, van Huizen E, Tolboom J, Schuitemaker H, Yao F PLoS One. 2024; 19(12):e0310250.

PMID: 39739963 PMC: 11687876. DOI: 10.1371/journal.pone.0310250.


NET-EN treatment leads to delayed HSV-2 infection, enhanced mucin and T cell functions in the female genital tract when compared to DMPA in a preclinical mouse model.

Mian M, Pa S, Rahman N, Gillgrass A, Kaushic C Front Immunol. 2024; 15:1427842.

PMID: 39569191 PMC: 11576457. DOI: 10.3389/fimmu.2024.1427842.


A review of HSV pathogenesis, vaccine development, and advanced applications.

Bai L, Xu J, Zeng L, Zhang L, Zhou F Mol Biomed. 2024; 5(1):35.

PMID: 39207577 PMC: 11362470. DOI: 10.1186/s43556-024-00199-7.


Towards a comprehensive view of the herpes B virus.

Lu J, Long Y, Sun J, Gong L Front Immunol. 2023; 14:1281384.

PMID: 38035092 PMC: 10687423. DOI: 10.3389/fimmu.2023.1281384.


Boosting of vaginal HSV-2-specific B and T cell responses by intravaginal therapeutic immunization results in diminished recurrent HSV-2 disease.

Bourne N, Keith C, Miller A, Pyles R, Cohen G, Milligan G J Virol. 2023; 97(9):e0066923.

PMID: 37655939 PMC: 10537585. DOI: 10.1128/jvi.00669-23.


References
1.
Lozzio C, LOZZIO B . Human chronic myelogenous leukemia cell-line with positive Philadelphia chromosome. Blood. 1975; 45(3):321-34. View

2.
Jerome K, Tait J, Koelle D, Corey L . Herpes simplex virus type 1 renders infected cells resistant to cytotoxic T-lymphocyte-induced apoptosis. J Virol. 1998; 72(1):436-41. PMC: 109392. DOI: 10.1128/JVI.72.1.436-441.1998. View

3.
Perussia B, STARR S, Abraham S, Fanning V, Trinchieri G . Human natural killer cells analyzed by B73.1, a monoclonal antibody blocking Fc receptor functions. I. Characterization of the lymphocyte subset reactive with B73.1. J Immunol. 1983; 130(5):2133-41. View

4.
Laird N, Ware J . Random-effects models for longitudinal data. Biometrics. 1982; 38(4):963-74. View

5.
Corey L, ADAMS H, Brown Z, Holmes K . Genital herpes simplex virus infections: clinical manifestations, course, and complications. Ann Intern Med. 1983; 98(6):958-72. DOI: 10.7326/0003-4819-98-6-958. View